144 results
Page 4 of 8
8-K
EX-99.1
bymxi 0afss91o
31 May 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
5p6a37f
23 May 22
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:30pm
8-K
EX-99.1
inin8h j13jyqic
1 Feb 22
Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board
6:45am
8-K
EX-99.1
a150v6
11 Jan 22
Regulation FD Disclosure
12:00am
8-K
EX-99.1
7wha gufrho
15 Dec 21
Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors
7:00am
8-K
EX-99.1
bjctxden
14 Dec 21
Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease
7:02am
8-K
EX-99.1
ttstj3draq
8 Nov 21
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s
7:32am
8-K
EX-99.1
yl6896kf490 tg4zn
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
8-K
EX-2.1
u34c9
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
8-K
EX-99.1
2m2rc mg8jw
14 Sep 21
Regulation FD Disclosure
4:20pm
8-K
EX-10.1
5958caz69j3axp
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-99.1
ego2r0t nmdgy7r7q37
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-10.2
eor1lqmmnhzvr
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am